Drug Trial Radar · NCT04285515
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
488
Actual
Start
Feb 27, 2020
Primary completion
Nov 30, 2022
Study completion Nov 30, 2022
Sponsor
- Lead sponsor
- Intra-Cellular Therapies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 26, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) or major depressive disorder (MDD) who also meet the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM-5) criteria for mixed-features. The study consists of a Screening Period, a Double-blind Treatment Period, and a Safety Follow-up Period.
Conditions
- Bipolar Depression
- Major Depressive Disorder
Interventions
LumateperoneDrug
Lumateperone 42mg oral capsule
PlacebosDrug
Placebo oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total ScoreTime frame: Day 43
Locations
42 sites in 5 countries. Site status is shown where the registry gives one.
Clinical Site
Garden Grove, California
Clinical Site
Oceanside, California
Clinical Site
Sherman Oaks, California
Clinical Site
Lauderhill, Florida
Clinical Site
Miami, Florida
Clinical Site
Orange City, Florida
Clinical Site
Atlanta, Georgia
Clinical Site
Decatur, Georgia
Clinical Site
O'Fallon, Missouri
Clinical Site
Cedarhurst, New York
Clinical Site
New York, New York
Clinical Site
Charlotte, North Carolina
Clinical Site
Bellevue, Washington
Clinical Site
Burgas, Bulgaria
Clinical Site
Kardzhali, Bulgaria
Clinical Site
Plovdiv, Bulgaria
Clinical Site
Rousse, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Varna, Bulgaria
Clinical Site
Veliko Tarnovo, Bulgaria
Clinical Site
Vratsa, Bulgaria
Clinical Site
Moscow, Russia
Clinical Site
Saint Petersburg, Russia
Clinical Site
Saint Petersburg, Russia
Clinical Site
Saint Petersburg, Russia
Clinical Site
Saint Petersburg, Russia
Clinical Site
Saint Petersburg, Russia
Clinical Site
Tomsk, Russia
Clinical Site
Yekaterinburg, Russia
Clinical Site
Belgrade, Serbia
Clinical Site
Kovin, Serbia
Clinical Site
Kragujevac, Serbia
Clinical Site
Kyiv, Ukraine
Clinical Site
Lviv, Ukraine
Clinical site
Odesa, Ukraine
Clinical Site
Odesa, Ukraine
Clinical Site
Poltava, Ukraine
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.